Introduction
============

The most common cause of cancer-related deaths worldwide is the lung cancer. Approximately 1.8 million patients were diagnosed with lung cancer and near 1.6 million lung cancer-related deaths occurred across the globe in 2012 (Siegel et al., 2018).

Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. It is clinically different from non-small cell lung cancer (NSCLC) because of its rapid progression and early development of metastases (Gaspar et al., 2005; Silvestri et al., 2013). Only 5% of all SCLC patients are diagnosed at the limited disease (LD) stage of the disease; the remaining patients get the diagnosis at the extensive disease (ED) stage. Highly greater probability of ED at the time of diagnosis can be attributed to the high degree of aggressive biology, rapid tumor progression, absence of symptoms in the early stage, and lack of well-established screening programs. Chemoradiotherapy (CRT) remains the standard treatment modality in LD-SCLC (Chen et al., 2010; Varlotto et al., 2011). On the other hand, potential prognostic factors are still unclear in this patient subset.

Platelets are responsible for initiating hemostatic mechanisms that abolish vascular endothelial injury (Smyth et al., 2009). Several recent studies have reported that platelets were associated with development and progression of malignancy (Riedl et al., 2014; Franco et al., 2015). Activated platelets were suggested to promote cancer cell growth, angiogenesis, and invasion (Buergy et al., 2012). Furthermore, association of some platelets indices were reported to prognosis in various cancers, including NSCLC, breast cancer, colorectal cancer, gastric cancer, pancreatic cancer, and laryngeal cancer. Several of these parameters, including total platelet count (TPC), mean platelet volume (MPV), platelet distribution width (PDW), and platelet-lymphocyte ratio (PLR) can be easily tested (Song et al., 2017; Zhang et al., 2017a; Zhang et al., 2017b). Nevertheless, the findings of studies reporting the association of platelet counts and other platelet indices to the presence and progression of cancer are still controversial and suggest the need for clarification (Monreal et al., 1998; Liu et al., 2017; Pedrazzani et al., 2017; Zhang et al., 2019).

This study aimed to investigate the effect of selected pretreatment platelet indices on survival of patients with LD-SCLC.

Materials and Methods
=====================

*Patients*

This retrospective study included patients who received concurrent chemoradiotherapy (CCRT) due to LD-SCLC in the oncology clinic between 1997-2017. Staging of patients were performed according to findings of pre-treatment fluorodeoxyglucose positron emission tomography (PET-CT), computed tomography (CT), and cranial magnetic resonance imaging (MRI). Tumor size was calculated by measuring the largest tumor diameter in CT. Exclusion criteria were malignancy other than SCLC, or those having ED-SCLC, autoimmune disease, history of aspirin or any immunosuppressive drug use, being under the age of 18, or whose data were not accessible. In our hospital, SCLC staging is performed based on PET-CT and cranial MRI findings, and pre-treatment clinical, pathological, and laboratory data are recorded. Ensuring a 10-12 hours of fasting, samples for blood tests are routinely taken from antecubital vein by establishing mild venous stasis at upper arm in patients who apply to oncology clinic before treatment. Blood samples for biochemical parameters are taken into the anticoagulant-free gel tubes, and those for complete blood counts into ethylenediamine tetraacetate-containing tubes. Complete blood count parameters are examined in hemogram autoanalyser (Mindray, China). Biochemical parameters are tested in autoanalyser (Beckman Coulter, USA) using colorimetric method. Based on Eastern Cooperative Oncology Group performance score (ECOG PS) and comorbidities, patients are treated with concomitant CRT of two cycles with platinum \[cisplatin (60-75 mg/m2) or carboplatin (AUC 5)\] + etoposide (100 mg/m2 for 1-3 days) at 28-day intervals, followed with two to four cycles of the same chemotherapeutic regimen at 21-day intervals. Radiotherapy is administered as a total of 60 Gy, consisting of 30 fractions as 2 Gy per day.

Data collection: Data on the age, gender, smoking status, ECOG PS, history of superior vena cava syndrome (SVCS), clinical tumor stage, chemotherapy regimen, cycle count, history of prophylactic cranial irradiation (PCI), presence of recurrence/metastasis, and survival status were obtained from medical records. In addition, initial laboratory values immediately after diagnosis were collected: creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), sodium, potassium, calcium, albumin, white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (Hb), hematocrit (Hct), mean corpuscular volume (MCV), total platelet count (TPC), total neutrophil count (TNC), total lymphocyte count (TLC), and total monocyte count (TMC). Neutrophil-lymphocyte ratio (NLR) was obtained by dividing the TNC by TLC. PLR was obtained by dividing TPC by TLC. Monocyte-lymphocyte ratio (MLR) was obtained by dividing the TMC by TLC. Patients were further stratified by their age as\<65 years and ≥65 years. Patients' ECOG PS were grouped as either 0-2 or 3-4. Receiver operating characteristics (ROC) curves were formed for overall survival (OS) using TPC, PDW, and PLR data at diagnosis. The areas under the curve (AUCs) were detected as 0.736 (95% CI 0.629-0.842, p\<0.001), 0.580 (95% Cl 0459-0702, p=0.197), and 0.405 (95% Cl 0.283-0,526, p=0.126), respectively. The cut-off value for TPC was determined as 306x10^9^/U with a sensitivity of 62% and a specificity of 75.5% ([Figure 1](#F1){ref-type="fig"}). Patients having a TLC of ≤306x10^9^/U were categorized as Group I and those having a TLC of \>306x10^9^/U were as Group II. OS was calculated as time from the diagnosis to the date of last follow-up or death. The study was performed in accordance with the declaration of Helsinki and was reviewed and approved by the Ethics Committee of the University of Health Sciences, Okmeydani Training and Research Hospital (26.2.18).

Statistical analysis: Statistical Package for the Social Sciences 22.0 for Windows software (Armonk NY, IBM Corp, 2013) was used for the statistical analysis. Descriptive statistics were presented as the mean, standard deviation, minimum, and maximum values for numerical variables. The comparison of the rates between the groups was performed by chi-square analysis. Numerical variable between two independent groups were analyzed with student t-test in case of normal distribution and with Mann Whitney U test if else. Monte Carlo simulation was applied if conditions could not be met. Survival analyses were performed with Kaplan-Meier Analysis. Determinant factors were examined with cox regression. Backward stepwise model was used with parameters having a p-value below 0.100. An overall 5% alpha error level was used to infer statistical significance.

###### 

Demographic and Clinical Characteristics of the Study Population

                                                                   All patient            Group 1                Group 2                                    
  -------------------------------------- ------------------------- ---------------------- ---------------------- ---------------------- ------- ---- ------ ---------
  Gender                                 Female                    18                     20                     8                      14.8    10   27.8   0.132
                                         Male                      72                     80                     46                     85.2    26   72.2   
  Age group                              \<65 years                70                     77.8                   41                     75.9    29   80.6   0.605
                                         ≥65 years                 20                     22.2                   13                     24.1    7    19.4   
  Smoking status                         No                        4                      4.4                    1                      1.9     3    8.3    0.144
                                         Yes                       86                     95.6                   53                     98.1    33   91.7   
  ECOG PS                                0-1-2                     77                     85.6                   44                     81.5    33   91.7   0.178
                                         3-4                       13                     14.4                   10                     18.5    3    8.3    
  SVCS                                   No                        84                     93.3                   51                     94.4    33   91.7   0.605
                                         Yes                       6                      6.7                    3                      5.6     3    8.3    
  Clinical stage                         I+II                      23                     25.6                   11                     20.4    12   33.3   0.167
                                         III                       67                     74.4                   43                     79.6    24   66.7   
  Chemotherapy regimen                   Cisplatin + etoposide     82                     91.1                   49                     90.7    33   91.7   0.879
                                         Carboplatin + etoposide   8                      8.9                    5                      9.3     3    8.3    
  PCI                                    No                        40                     44.4                   28                     51.9    12   33.3   0.083
                                         Yes                       50                     55.6                   26                     48.1    24   66.7   
  Relapse/metastasis                     No                        19                     21.1                   9                      16.7    10   27.8   0.206
                                         Yes                       71                     78.9                   45                     83.3    26   72.2   
  Final status                           Alive                     37                     41.1                   14                     25.9    23   63.9   \<0.001
                                         Exitus                    53                     58.9                   40                     74.1    13   36.1   
  Age (years)                            Mean (Min-Max)            59.0 (42-83)           60.0 (42-77)           58.0 (46-83)           0.166               
  Smoking (pack-years)                   Mean ± SD (Min-Max)       57.8 ± 34.7 (0-180)    57.6 ± 30.8 (0-180)    58.0 ± 40.3 (0-160)    0.67                
  Tumor size (cm)                        Mean ± SD (Min-Max)       5.8 ± 2.6 (2.0-15.0)   5.4 ± 2.2 (2.0-10.5)   6.5 ± 3.1 (2.0-15.0)   0.131               
  The number of cycles of chemotherapy   Mean ± SD (Min-Max)       4.9 ± 1.1 (2-6)        4.8 ± 1.2 (2-6)        5.1 ± 1.0 (3-6)        0.268               

ECOG PS, Eastern Cooperative Oncology Group Performance Status; PCI, prophylactic cranial irradiation; SVCS, superior vena cava syndrome.

![ROC Curve Analyses for OS; platelets are represented by the line with AUC = 0.736 (95% CI, 0.629--0.842; p\<0.001) with a sensitivity of 62.2% and a specificity of 75.5% (306x103). AUC, the area under the curve, PDW, platelet distribution width, PLR, platelet-to-lymphocyte ratio](APJCP-20-1879-g001){#F1}

###### 

Baseline Laboratory Parameters of the Study Population

                       All patient   Group 1                      Group 2                                                                  
  -------------------- ------------- ---------------------------- --------- --------------------------- ---- ----------------------------- ---------
  Creatinine (mg/dL)   84            0.8 ± 0.2 (0.3-1.5)          49        0.8 ± 0.2 (0.5-1.5)         35   0.8 ± 0.2 (0.3-1.3)           0.114
  AST (U/L)            79            22.4 ± 12.6 (9-79)           47        24.1 ± 14.3 (10-79)         32   19.8 ± 9.0 (9-60)             0.24
  ALT (U/L)            79            22.1 ± 15.3 (7-104)          47        21.4 ± 13.0 (7-64)          32   23.3 ± 18.4 (7-104)           0.869
  GGT (U/L)            58            52.7 ± 77.6 (8-467)          33        61.3 ± 99.3 (8-467)         25   41.4 ± 30.3 (10-153)          0.081
  LDH (U/L)            57            259.3 ± 119.4 (120-671)      31        259.2 ± 101.9 (120-560)     26   259.5 ± 139.5 (120-671)       0.718
  ALP (U/L)            57            114.1 ± 88.7 (15-546)        33        119.3 ± 97.8 (35-546)       24   107.1 ± 75.9 (15-340)         0.821
  Sodium (mmol/L)      43            139.3 ± 3.3 (130-146)        25        139.0 ± 3.7 (130-145)       18   139.7 ± 2.6 (134-146)         0.804
  Potassium (mmol/L)   41            4.5 ± 0.4 (3.8-5.5)          23        4.5 ± 0.5 (3.8-5.5)         18   4.4 ± 0.4 (3.9-5.2)           0.252
  Calcium (mg/dL)      40            9.5 ± 0.4 (8.5-10.7)         25        9.6 ± 0.5 (8.5-10.7)        15   9.5 ± 0.2 (9.0-9.9)           0.474
  WBC (10^9^/U)        90            8.9 ± 3.5 (2.5-25.5)         54        8.3 ± 3.2 (2.5-21.1)        36   9.9 ± 3.9 (4.4-25.9)          0.011
  Rbc (10^9^/U)        90            4.5 ± 0.6 (3.0-6.4)          54        4.6 ± 0.7 (3.0-6.4)         36   4.4 ± 0.4 (3.4-5.2)           0.076
  Hb (g/dL)            90            12.9 ± 1.7 (9.3-17.3)        54        13.3 ± 1.8 (9.3-17.3)       36   12.3 ± 1.5 (9.7-15.2)         0.004
  Hct (%)              90            39.2 ± 5.0 (27.6-49.5)       54        40.3 ± 5.2 (27.6-49.5)      36   37.5 ± 4.2 (30.1-46.0)        0.005
  MCV (fL)             90            86.7 ± 6.8 (64.1-102.2)      54        87.6 ± 6.5 (67.1-102.2)     36   85.3 ± 7.2 (64.1-98.6)        0.12
  TPC (10^9^/U)        90            302.9 ± 128.3 (38.8-798.0)   54        222.4 ± 56.8 (38.8-305.0)   36   423.6 ± 109.7 (307-798)       \<0.001
  PDW (%)              90            14.8 ± 7.9 (8.2-64.4)        54        16.0 ± 9.8 (8.2-64.4)       36   13.0 ± 3.0 (8.2-17.4)         0.124
  MPV (fL)             90            8.9 ± 1.5 (5.3-13.1)         54        9.2 ± 1.6 (5.8-13.1)        36   8.4 ± 1.4 (5.3-10.4)          0.04
  RDW (%)              81            14.5 ± 1.7 (12.0-19.4)       48        14.5 ± 1.9 (12.1-19.4)      33   14.4 ± 1.5 (12.0-19.2)        0.893
  TNC (10^9^/U)        90            6.1 ± 3.2 (1.6-23.6)         54        5.5 ± 2.8 (1.6-18.5)        36   6.8 ± 3.6 (2.4-23.6)          0.011
  TLC (10^9^/U)        90            1.9 ± 0.8 (0.4-3.4)          54        1.9 ± 0.8 (0.4-3.4)         36   2.0 ± 0.7 (0.5-3.4)           0.424
  TMC (10^9^/U)        90            0.7 ± 0.3 (0.1-2.0)          54        0.6 ± 0.3 (0.1-1.4)         36   0.7 ± 0.3 (0.4-2.0)           0.168
  NLR                  90            3.5 ± 2.8 (1.1-20.1)         54        3.3 ± 2.5 (1.1-16.8)        36   3.9 ± 3.3 (1.1-20.1)          0.236
  PLR                  90            180.4 ± 120.8 (19.4-761.1)   54        138.5 ± 77.6 (19.4-455.6)   36   243.2 ± 145.6 (100.6-761.1)   \<0.001
  MLR                  90            0.4 ± 0.3 (0.1-2.0)          54        0.4 ± 0.2 (0.1-1.3)         36   0.4 ± 0.3 (0.2-2.0)           0.595

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; Hb, hemoglobin; Hct, hematocrit; GGT, gamma glutamyl transferase; LDH, lactate dehydrogenase; MCV, mean corpuscular volume; MLR, monocyte-to-lymphocyte ratio; MPV, mean platelet volume; NLR; neutrophil-to-lymphocyte ratio; PDW, platelet distribution width; PLR, platelet-to-lymphocyte ratio; RBC, red blood cell; RDW, red cell distribution width; TLC, total lymphocyte count; TMC, total monocyte count; TNC, total neutrophil count; TPC, total platelet count; WBC, white blood cell.

###### 

Univariate Analysis for OS

  Variable                                                 HR      95% CI         p
  -------------------------------------- ----------------- ------- -------------- ---------
  Gender                                 male vs. female   1.512   0.711-3.215    0.283
  Age                                    years             1.045   1.013-1.078    0.006
  Smoking status                         no vs. yes        1.824   0.438-7.599    0.409
  ECOG PS                                2-4 vs. 0-1       4.393   2.258-8.545    \<0.001
  Clinical stage                         stage 3 vs. 1-2   6.167   2.579-14.746   \<0.001
  PCI                                    yes vs. no        0.327   0.188-0.570    \<0.001
  The number of cycles of chemotherapy   ≤4 vs. \>4        0.483   0.277-0.842    0.01
  Smoking                                pack-years        0.999   0.992-1.006    0.826
  Tumor size                             cm                0.92    0.820-1.032    0.156
  Creatinine                             mg/ dL            1.661   0.415-6.647    0.473
  AST                                    U/L               1.008   0.987-1.029    0.463
  ALT                                    U/L               0.999   0.977-1.022    0.954
  GGT                                    U/L               1.003   1.000-1.007    0.081
  LDH                                    U/L               1       0.997-1.002    0.81
  ALP                                    U/L               0.999   0.994-1.004    0.689
  Sodium                                 mmol/L            0.963   0.855-1.085    0.534
  Potassium                              mmol/L            2.602   0.998-6.785    0.055
  Calcium                                mg/ dL            0.556   0.181-1.710    0.306
  WBC                                    10^9^/U           0.971   0.896-1.053    0.478
  RBC                                    10^9^/U           0.936   0.582-1.505    0.785
  Hb                                     g/dL              1.057   0.905-1.236    0.483
  Hct                                    \%                1.017   0.962-1.074    0.556
  MCV                                    fL                1.025   0.983-1.070    0.24
  TPC                                    10^9^/U           0.996   0.994-0.999    0.002
  PDW                                    \%                1.033   1.003-1.065    0.031
  MPV                                    fL                1.092   0.917-1.300    0.325
  RDW                                    \%                1.102   0.921-1.318    0.29
  TNC                                    10^9^/U           0.971   0.891-1.058    0.5
  TLC                                    10^9^/U           1.031   0.700-1.517    0.878
  TMN                                    10^9^/U           1.054   0.401-2.770    0.915
  NLR                                                      0.979   0.893-1.075    0.662
  PLR                                                      0.997   0.994-1.000    0.028
  MLR                                                      1.186   0.410-3.432    0.753

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; ECOG PS, Eastern Cooperative Oncology Group; Hb, hemoglobin; Hct, hematocrit; GGT, gamma glutamyl transferase; LDH, lactate dehydrogenase; MCV, mean corpuscular volume; MLR, monocyte-to-lymphocyte ratio; MPV, mean platelet volume; NLR; neutrophil-to-lymphocyte ratio; PCI, prophylactic cranial irradiation; PDW, platelet distribution width; PLR, platelet-to-lymphocyte ratio; RBC, red blood cell; RDW, red cell distribution width; SVCS, superior vena cava syndrome; TLC, total lymphocyte count; TMC, total monocyte count; TNC, total neutrophil count; TPC, total platelet count; WBC, white blood cell.

###### 

Multivariate Analysis for OS

  Variable                       HR      95% CI         p
  ---------------- ------------- ------- -------------- ---------
  ECOG PS          2-4 vs. 0-1   2.849   1.441-5.633    0.003
  Clinical stage   3 vs. 1-2     5.542   2.277-13.489   \<0.001
  PCI              Yes vs. No    0.447   0.248-0.805    0.004
  TPC              10^9^ /U      0.997   0.995-0.999    0.031

ECOG PS, Eastern Cooperative Oncology Group; PCI, prophylactic cranial irradiation; TPC, total platelet count.

![Overall Survival by (A) Clinical Stages, (B) Platelet Groups; (C) Platelet Groups in Stage I+II, and (D) Platelet Groups in Stage III](APJCP-20-1879-g002){#F2}

Results
=======

The study included 90 patients whose mean age was 59 years (range: 42-83), and male cases constituted 80.0% (n=72). Twenty patients (22.2%) were ≥65 years old. Most of patients (95.6%) had history of smoking. Thirteen patients (14.4%) had ECOG PS of ≥2. SVCS was present at time of diagnosis in six patients (6.7%). A quarter of patients (25.6%) were at clinical stage I or II. Patients received mostly (91.1%) cisplatin + etoposide protocol, with a mean number of 4.9 cycles overall. PCI was performed in 50 patients (55.6%). During the follow-up, 71 (78.9%) patients had relapse/metastasis and 53 (58.9%) patients had died. There were 54 patients (60.0%) in Group I and 36 patients (40.0%) in Group II. These study groups were found as similar in terms of age, gender, smoking status, ECOG PS, tumor localization, presence of SVCS, clinical stage, chemotherapy regimen, received cycle count, and relapse/metastasis rates ([Table 1](#T1){ref-type="table"}).

Group I had significantly higher levels of mean baseline Hb, Hct, and MPV (p=0.004, p=0.005, and p=0.040; respectively) and significantly lower levels of mean baseline WBC, TNC, and PLR (p=0.011, p=0.011, and p\<0.001; respectively) compared to those in Group II. All other laboratory values did not significantly differ between these study groups ([Table 2](#T2){ref-type="table"}).

Median overall survival (mOS) was significantly higher in patients with clinical stage I or II compared to that in patients with clinical stage III (126 \[range: 29.2-281.5\] vs. 19 \[range: 16.3-31.6\] months, respectively; log rank p\<0.001). mOS in Group I (17 \[range: 13.3-20.6\] months) was significantly lower than that in Group II (70 \[range: 21.3-118.6\] months; log rank p\<0.001). Among stage I-II patients, mOS was found as 126 months for Group I whereas it had not been reached in Group II (log rank p=0.158). Stage III patients showed significantly lower mOS for Group I (16 \[range: 14.1-17.8\] months) compared to that in Group II (19.0 \[range: 15.6-62.8\] months; log rank p=0.002), ([Figure 2](#F2){ref-type="fig"}).

Univariate analysis showed the age, ECOG PS, clinical stage, PCI, number of chemotherapy cycles, TPC, PDW, and PLR as the significant factors that affected survival (p=0.006, p\<0.001, p\<0.001, p\<0.001, p=0.010, p=0.002, p=0.031, and p=0.028; respectively), ([Table 3](#T3){ref-type="table"}). In further multivariate analysis, Eastern Cooperative Oncology Group performance score (p=0.003), clinical stage (p\<0.001), prophylactic cranial irradiation (p=0.004), and TPC (p=0.031) was determined as the most significant factors affecting survival, ([Table 4](#T4){ref-type="table"}).

Discussion
==========

In this study, we investigated the effect of pre-treatment TPC, MPV, PDW, and PLR on survival of LD-SCLC patients managed with CRT. Interestingly, a higher TPC (\>306x10^3^) was associated with improved survival in clinical stages I to III.

SCLC is known to have a more aggressive behavior than does NCSLC. In recent years, mean life expectancy has been improved owing to novel targeted therapy and immunotherapy modalities (Gadgeel et al., 2018; Uemura and Hida, 2018). However, survival in SCLC has not been much changed despite improvements in treatment options in the last 15 years (Gaspar et al., 2012). A recent study reported 2 months of improved survival with add-on atezolizumab to chemotherapy in ED-SCLC (Horn et al., 2018). All these indicate that the need for the development of simple and feasible prognostic factors in SCLC is extremely important.

Inflammatory biomarkers reflect the responses of the host against malignant cells. Lately, there is a growing interest of the host's inflammatory response against the tumor. Several studies have proposed NLR, PLR, and TPC as indicators of inflammatory conditions, and these indicators were described as both prognostic and predictive biomarkers in some cancers (Monreal et al., 1998; Forget et al., 2013; Lee et al., 2013; Pedrazzani et al., 2017; Song et al., 2017; Zhang et al., 2017a).

Currently, there are many articles discussing the effect of thrombocytosis on survival in NSCLC (Pedersen and Milman, 1996; Aoe et al., 2004; Tomita et al., 2009; Hong et al., 2015; Xie et al., 2015; Hong et al., 2018). However, there is scarce data on the prognostic importance of pre-treatment of TPC, MPV, PDW, and PLR in SCLC. Previous studies have reported mainly unfavorable or no impact of high platelet counts on survival of patients with NSCLC (Pedersen and Milman, 1996; Aoe et al., 2004; Tomita et al., 2009; Cakar et al., 2011).

Xie et al., (2015) in their study of 383 Chinese LD-SCLC patients reported low Hb, high PLR and NLR to be associated with poor prognosis; and determined important prognostic variables as PLR, age, smoking cessation, radiotherapy, chemotherapy, surgery, and PCI. Zhang et al., (2019) compared patients with high PLR (\>152.1) to those with lower levels in their study regarding 286 Chinese LD-SCLC patients, and found mOS as 19.5 vs. 27.4 months, respectively; and concluded pre-treatment PLR as an independent variable for OS.

Bernhardt et al., (2018) performed a study with 350 German LD-SCLC patients managed with CRT, where they reported no effect of NLR, age, Hb, and TPC on survival. The authors stated that multivariate analysis showed PCI, LDH, and CRP as independent factors affecting survival. Suzuki et al., (2019) in their study of 122 LD-SCLC patients who received CRT and followed up between 2002 and 2015, detected that lymphopenia was an independent poor prognostic factor.

Liu et al., (2017) determined NLR but not PLR as an independent prognostic factor in their study of 139 Chinese patients (55 LD-SCLC, 83 ED-SCLC). Hong et al., (2015) reported PLR, NLR, Hb, and MCV as significant prognostic factors in multivariate analysis in their study of 919 Chinese patients consisting of 552 LD-SCLC and 352 ED-SCLC cases, where the former group had a mOS of 11.8 months (Hong et al., 2015). Another study by Hong et al., (2018) among the 590 patients with LD-SCLC showed LDH, number of cycles of chemotherapy, and recurrence but not TPC as the independent factors affecting OS. Similarly, Deng et al. performed a study with 320 Chinese patients (122 LD-SCLC and 198 ED-SCLC), where they reported pre-treatment increased LDH and NLR but not PLR as an independent poor prognostic factor (Deng et al., 2017).

In our study, ECOG PS, clinical stage, PCI, and TPC were found to be independent factors affecting survival. All other laboratory parameters including NLR, PLR, MLR, TLC, MPV, and PDW were not associated with OS. The majority of studies about SCLC were performed on Chinese patients, among which treated with CRT had a mOS 11.2 to 27.4 months (Hong et al., 2015; Xie et al., 2015; Deng et al., 2017; Liu et al., 2017; Hong et al., 2018; Zhang et al., 2019). In our study, mOS was found as 25 months in all patients, including 126 months in stage I or II and 19 months in stage III. We did not measure the impact of ethnicity on our findings. For instance, German patients who received treatment with CRT had a mOS of 48 months (Kasmann et al., 2017).

Our study has several limitations. Although our study was performed only with LD-SCLC patients that received concomitant CRT with platinum + etoposide, we only included Turkish patients in a single-center setting with retrospective fashion. We cannot fully explain the mechanism of the effect of TPC on patients' prognosis in LD-SCLC. We also do not know the degree of impact of ethnicity on our conclusions. We believe that our results warrant confirmation by studies involving more comprehensive studies with larger sample size.

In conclusion, our study suggests association of elevated TPC before treatment to prognosis in patients who received concomitant CRT with platinum + etoposide due LD-SCLC. Considering easiness and universal availability of TPC measurement, potential utilization of this biomarker may be promising to predict survival, albeit requiring validation by further well-designated prospective studies.
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